BERTIS

Diseases are the biggest threats to our healthy lives.
Proteomic information offer signs of disease manifestation.
Bertis is committed to developing proteomics-based clinical solutions,
enhanced by AI technology, to fight diseases.

Since its incorporation in 2014, Bertis, a leading proteomics company in Asia,
has combined its unrivaled proteomics research capabilities with AI and bioinformatics technologies.
Using our proprietary DEEP platform to analyze large-scale protein data generated by mass spectrometry,
we support drug development for pharmaceutical and biotech companies (PASS)
and provide blood-based early cancer diagnostic tests (CHECK).

Promoting early diagnosis for major diseases is indeed the most effective way to provide medical benefits to people with limited resources. This is the reason why we started by developing a breast cancer screening solution based on blood tests, which are readily accessible in the clinical fields.

: Dong-young Noh,
Co-CEO

Successful commercialization of proteomics-based diagnostic solutions with AI: Bertis has unrivaled technological prowess in the field of quantitative proteomics.
We have a core technology platform that cover the overall processes starting from the discovery of protein biomarkers to the development of diagnostic solutions. Based on this, research and development are being conducted on diagnostic solutions for cancers and major diseases. While global proteomics companies do not have commercially available disease diagnosis products to date, Bertis successfully commercialized “MASTOCHECK,” a breast cancer blood test that utilizes proteomics technologies, in 2019 for the first time in the world.

The significance of proteomics technology can be seen in its ability to provide early diagnosis and tailored treatment of diseases more economically at a higher quality. To implement and maximize the potential of proteomics technologies in actual clinical settings, we strive to advance bioinformatics and software technologies to the cutting edge and actively apply them to the research and development of new drugs and innovative therapeutic agent.

: Seung-man Han,
Co-CEO

Pursuing to maximize clinical utility that innately embedded within proteomics technology: Bertis has been dedicated to advancing bioinformatics and software technologies to maximize the utility of proteomics in diagnosing and precision medicine. Based on these state-of-the-art technologies and expertise that have successfully commercialized proteomics-based solutions, we are promoting collaborations in research and development with top-tier domestic and international partners as well as providing analysis solutions that can increase the R&D success rate to allow more active development and introduction of new drugs and innovative therapeutic agents.

HISTORY Since 2014 ~

2022~

2020~2021

2019

2014~2018

2026

10

Selected for Specialized Type of Scale-Up TIPS Program

07

Won Judges’ Selection at MSD Health Innovation Summit

03

Signed Joint Research Agreement with Vanderbilt

2025

10

Supported Mechanism-of-Action Elucidation for Hanmi Pharmaceutical’s HM17321

07

Signed MASTOCHECK Supply Agreement with Innoquest Diagnostics

04

SNE-101 Phase 1 Clinical Trial Approved (Supported by PASS Proteomics Analysis)

2024

04

Secured Pre-IPO Investment

2023

10

Signed a supply agreement for MASTOCHECK with 7 countries in the Middle East

09

Participation in HUPO 2023 (Human Proteome Organization World Congress)

2022

12

MASTOCHECK, Entry to APAC Region Starting with Singapore

11

MASTOCHECK selected as a “2022 Next-Generation World Class Product” by MOTIE

07

MASTOCHECK Available in Clinical Practice as an After-Entry Medical Technology

05

Launched Pan-omics Analysis Solution ‘PASS(Pan-omics Analysis Service & Solution)’

2021

12

Biomarker research institute, located in Bundang-gu, named as an Excellent Corporation R&D Center

07

MOU agreement with National Cancer Center Research Institute for the development of proteomics-based cancer diagnosis and treatment

04

MOU agreement with Seoul National University Hospital Gangnam Center for plasma proteome analysis

03

Inauguration of co-CEO, Dong-young Noh
MOU agreement with Medical IP, the medical AI solution company

2020

11

Selected as one of the 1000 National Innovative Enterprise by the Financial Services Commission, and Ministry of Health and Welfare

05

Selected as an Innovation Icon by the Korea Credit Guarantee Fund
Selected as a “Research Institute Designated for Military Service” by the Military Manpower Administration

2019

12

Established an affiliated research institute in Giheung
Concluded a domestic and overseas (Japan and China)
patent technology transfer contract with Kyung Hee and three other universities
Registration No.: 10-1795689 (Korea), 2015-80079529 (China), 6,441,504 (Japan)

11

Concluded domestic technology transfer contracts with Seoul National University for two patents
Registration No.: 10-09911289, 10-1096928
Selected as a “First Penguin-type Start-up Business” by the Korea Credit Guarantee Fund

10

Concluded a business agreement with Fraunhofer-Gesellschaft in Germany, one of Europe’s representative research institutes
Acquired Medical Device Quality Management System (ISO 13485) certification

09

Acquired New Excellent Technology (NET) certification for MASTOCHECK

07

Concluded a research service development agreement with the DGIST Core Protein Resources Center
Obtained approval for building and operating a living modified organism (LMO) research facility
Registered as a medical device sales business (No. 8657)

06

MASTOCHECK research results presented at the American Society of Clinical Oncology 2019 (ASCO 2019)

02

Obtained Korea Good Manufacturing Practices of Medical Devices (GMP) certification

01

Obtained a medical device license from the Ministry of Food and Drug Safety (In-vitro Medical Device No. 19-5)
Filed a patent in the U.S.
Registration No.: 10.184.943

2018

10

Obtained a medical device manufacturing business license
from the Ministry of Food and Drug Safety (In-vitro No. 6241)

06

Incorporated Bertis Health Care Sales

2017

12

Obtained venture company certification
Established an affiliated research institute in Seongnam

02

Filed a patent in Japan
Registration No.: 6096813

01

Filed a patent in China
Registration No.: ZL201380013325.7
Concluded foreign patent (China, U.S. and Japan)
technology transfer contracts with Seoul National University

2015

07

Concluded domestic technology transfer contracts with Seoul National University for six patents
Registration No.: 10-1431062, 10-1431063, 10-1431064, 10-1431065, 10-1431066, 10-1431067

2014

12

Incorporation

CERTIFICATIONS

“MASTOCHECK,” which is an integration of the core technologies of Bertis, was recognized for its excellence and obtained a product license from the the Ministry of Food and Drug Safety(MFDS) in 2019 as an algorithmic medical device that uses multiple markers. Furthermore, the product obtained the New Excellent Technology (NET) certification from the Ministry of Health and Welfare in the medical science field for the first time in 10 years.